53 results about "Cancer screening" patented technology

The invention discloses a method, a system, equipment and a medium for detecting an HPV (human papilloma virus) DNA (deoxyribonucleic acid) integration event, and relates to the technical field of gene detection. According to the method, HPV types and virus loads (Ct values) pre-screened by qPCR are used as natural identifiers to guide grouping and mixing of samples, and HPV integrated event detection and sample tracing are synchronously realized through single sequencing. Clinical verification shows that compared with qPCR, the comprehensive sensitivity reaches 97.1%, and the cost is reduced by 60%. And a built-in targeted retest mechanism improves the reliability of a detection result. The invention provides a novel, traceable, economical and feasible solution, is used for high-throughput HPV-host genome integration feature analysis, balances cost, expandability and clinical accuracy, and provides a high-throughput and low-cost solution for HPV-related cancer screening.

To provide a method for screening an olfactory receptor protein or its combination useful in cancer examination.SOLUTION: A method for screening an olfactory receptor protein or a combination thereof, comprising testing the reactivity of a test olfactory receptor protein to cancer, and selecting at least one selected from the group consisting of (1) a combination of the olfactory receptor protein A and the olfactory receptor protein C, (2) a combination of the olfactory receptor protein A ' and the olfactory receptor protein B, and (3) the olfactory receptor protein B '.SELECTED DRAWING: None

Methods and systems for detection and diagnosis of oral lesions and application of treatment are described. One example mobile intraoral system includes an intraoral probe with a plurality of windows and a first plurality of light sources positioned in its distal section. The intraoral probe also includes one or more additional light sources operable at one or more wavelengths in the range 600 nm to 700 nm, one or more heat sinks, and one or more optical waveguides coupled to the additional light sources. The mobile intraoral system is selectively operable in a first mode of operation for imaging and diagnosis of suspicious regions in the oral cavity, and a second mode of operation for administering photodynamic therapy (PDT). The intraoral probe's distal section is bendable to allow insertion in the oral cavity and targeting a particular location of the oral cavity for administration of the PDT.

The embodiment of the invention provides an image processing method and a CT image processing method, and the image processing method comprises the steps: receiving an image processing task which carries a plurality of target images which comprise at least one to-be-detected region, the image processing task is used for determining whether an abnormal object exists in each to-be-detected area; and inputting the plurality of target images into an image processing model to obtain a detection result corresponding to each to-be-detected area, the detection result including detection labeling information, detection category information and a detection guidance text. According to the method, efficient abnormal object recognition can be performed on multiple to-be-detected areas in the target image, the detection efficiency and accuracy are improved, and the problems of missing detection and false detection in a traditional method can be avoided. The multi-cancer screening can be realized, meanwhile, a clearer, more visual and interpretable auxiliary diagnosis basis can be provided for medical personnel, and the convenience and decision-making quality of clinical work are improved.

Disclosed is a machine learning method for curating biomarker panel, for screening of cancer(s) and system therefor, addressing the critical need for early detection through a combination of innovative biomarker research, advanced computational algorithms and integration with existing healthcare infrastructure. The biomarker panel is curated to facilitate pan-cancer screening of the patient with high sensitivity and specificity using the ML method deploying MoE (Mixture of Expert) models for accurate screening, thereby enhancing diagnostic accuracy and also empowering clinicians with actionable insights, thereby improving patient prognosis and facilitating personalized treatment strategies.

The invention provides a biomarker and a kit for pancreatic cancer screening, and belongs to the technical field of cancer screening. According to the technical scheme, urine proteins of pancreatic cancer patients are screened in a large range, early pancreatic cancer patients are taken as target samples, two specific amino acid fragments are determined, the content of the two specific amino acid fragments in non-pancreatic cancer patients is extremely low, the two specific amino acid fragments are only massively expressed in the patients, and the two specific amino acid fragments can be accurately detected in urine of the early pancreatic cancer patients. Benefited from the specific markers, the invention designs a kit and a detection method for pancreatic cancer screening, according to the method, urine total protein is extracted, enzymolysis, desalination and drying are performed, liquid chromatography-mass spectrometry analysis is performed, and whether a target peak appears on a chromatogram or not is taken as a judgment basis. The screening scheme is high in specificity and sensitivity, simple and convenient to operate, capable of effectively improving the discovery rate of the early pancreatic cancer and good in popularization prospect.

The present invention relates to storing and testing for abnormalities in cell free DNA (cfDNA) from blood, such as in maternal blood or blood for cancer screening.

Methods of using detection of PD-L1 expression by circulating cancer cells in the screening, monitoring, treatment and diagnosis of cancer in subjects are disclosed. The methods are based on assaying one or more of circulating tumor cells (CTCs), epithelial to mesenchymal transition CTCs (EMTCTCs), cancer associated macrophage-like cells (CAMLs), and cancer associated vascular endothelial cells (CAVEs) isolated from a subject having cancer for PD-L1 expression.

Provided herein are kits and methods useful for cancer screening, diagnosis, research and therapy. In particular, provided herein are methods of screening, diagnosing, and / or treating prostate cancer based on expression levels of cancer markers.

The present invention relates to a method of screening for or surveillance of a disease or cancer in a biological sample obtained from an individual, comprising detecting the presence of one or more disease or cancer biomarkers on or in extracellular vesicles particles (EPs) in an enriched fraction of EPs which are secreted or released from cells of a tissue of a defined category. The method of screening for or surveillance of a disease or cancer comprises obtaining an enriched fraction of EPs from a particular tissue, and detecting the presence of one or more disease or cancer biomarkers on or in EPs in the enriched fraction of EPs. Also provided are a method of identifying a disease or cancer biomarker present at reduced or elevated level on or in EPs in an enriched fraction of EPs which are secreted or released from cells of a tissue of a defined category, a system for analysing a biological sample obtained from an individual comprising an biomarker detection subsystem and a processor couplable to the biomarker detection subsystem, a use of one or more cancer biomarkers in the detection of cancer in a biological sample obtained from an individual, and an antibody and a primer, and uses thereof, for the detection of cancer of a tissue of a defined category in a biological sample obtained from an individual.

Disclosed is the characterization of nucleic acids obtained from cancer-associated cells circulating in the blood of a subject, and the use of such characterization in the screening, diagnosis, treatment, and recurrence of cancer. [Selection diagram] Figure 4

Controls for the identification of various genotypes and / or for the identification or characterization of a disease or condition are described. These controls can be especially useful for diagnostic tests that use circulating cell-free DNA or microRNA. A control may consist of a mixture of nucleic acids. In some formulations, a control comprises liposomes, for example, where the nucleic acids of the control are associated with the liposomes. For example, controls are useful for determining whether a fetus has aneuploidy. Methods for using these controls are also described.

The present invention provides a combination of epithelial and stromal biomarkers that are useful for determining whether a subject has a high or low probability of developing a tumor.In particular, the present invention provides a method for screening, detecting or monitoring tumors in a subject, the method comprising combining the expression levels of KRT19 and COL1A2 to generate a score, and determining whether a subject has a high or low probability of developing a tumor based on the score.

A method for pre-screening a subject for cancer is disclosed. Genetic risk associated with a gene signature is calculated by sequencing and analyzing cell-free DNA ("cfDNA") fragments present in a subject's blood sample. Clinical risk is calculated based on factors such as age, sex, and race. In some cases, clinical factors specific to a particular cancer, such as smoking status, are also incorporated. Incorporating clinical risk into genomic risk analysis improves lung cancer pre-screening results, enabling the detection of the same number of positive cancers using fewer LDCT lung cancer screening sessions.

The invention discloses a visual paper-based cancer miRNA marker detection kit, the kit comprises an integrally formed foldable T-shaped filter paper, and a DNA probe TEprobe, urease and a color developing agent dropwise added on the filter paper, and the principle of the kit is as follows: the TEprobe is combined with a cancer nucleic acid marker (miRNA) to release Ag < + > to inhibit the activity of the urease; the composite signal response of the pH response probe phenol red and fluorescein is triggered, and the detection sensitivity is as low as 10-12 M. The kit provided by the invention can significantly shorten the detection time and reduce the sample demand, and realizes zero false positive rate and 97.10% specificity by combining with machine learning algorithm classification during result analysis. The performance is successfully verified in real samples of prostatic cancer, liver cancer and colorectal cancer, and a cheap and convenient means is expected to be provided for family self-inspection and cancer screening and diagnosis in resource-deficient areas.

The invention discloses a liver cancer screening system based on platelet alpha particle super-resolution imaging, which combines the proportion of alpha particle'regular distribution 'platelets and clinical indexes AFP and DCP to screen liver cancer, and can improve the sensitivity of early hepatocellular carcinoma screening. Besides, according to the cancer broad-spectrum screening system provided by the invention, the proportion of alpha-particle'regular distribution 'platelets or the proportion of alpha-particle'N < = 30' platelets is taken as a cancer broad-spectrum screening marker, and the higher the proportion of the alpha-particle'regular distribution 'platelets or the lower the proportion of alpha-particle'N < = 30' platelets is, the higher the proportion of alpha-particle'regular distribution 'platelets is or the lower the proportion of alpha-particle'N < = 30' platelets is. When the cancer risk is higher, cancer broad-spectrum screening is carried out, and high specificity and sensitivity are achieved.

The invention provides an artificial-intelligence–based platform for automated analysis of Pap smear slides. The system integrates preprocessing, dual deep learning models (CNN-Transformer and EfficientNet-LSTM), and reporting modules to classify cytological images into diagnostic categories including NILM, ASC-US, LSIL, HSIL, and SCC. The platform includes interpretability outputs, secure data management, and active learning capabilities, enabling scalable, accurate, and transparent cervical-cancer screening across diverse laboratory settings. The platform is suitable for implementation in clinical pathology laboratories, telemedicine networks, and population-level screening programs. It allows rapid, reproducible, and objective evaluation of cytology slides, improving throughput while reducing reliance on manual slide examination. The invention is deployable on local servers, private clouds, or public cloud infrastructures and is adaptable to various cytology specimens. Adoption of this system enhances early detection of precancerous lesions, reduces inter-observer variability, and facilitates integration with laboratory information systems. It also supports continuous learning and adaptation to evolving imaging protocols. The invention provides multiple advantages over existing methods: (1) Dual-model architecture combining CNN-Transformer and EfficientNet- LSTM ensures robust classification across both dense and sparse cellular regions. (2)Preprocessing and adaptive tiling improve feature extraction from variable-quality images. (3)Interpretability modules enhance clinician trust and facilitate regulatory compliance. (4) Active learning allows continuous improvement based on expert feedback. (5) Modular deployment supports both local laboratory and cloud-based operation. (6) Data security features meet international standards for privacy and encryption. (7) High scalability enables screening of large slide volumes without compromising accuracy. The invention provides a clinically relevant, efficient, and technologically advanced solution for automated cervical-cancer screening, applicable in diverse healthcare environments and adaptable to future cytology domains.

Methods for creating a selector of mutated genomic regions and for using the selector set to analyze genetic alterations in a cell-free nucleic acid sample are provided. The methods can be used to measure tumor-derived nucleic acids in a blood sample from a subject and thus to monitor the progression of disease in the subject. The methods can also be used for cancer screening, cancer diagnosis, cancer prognosis, and cancer therapy designation.

To provide a method for screening an olfactory receptor protein or its combination useful in cancer examination.SOLUTION: A method for screening an olfactory receptor protein or a combination thereof, comprising testing the reactivity of a test olfactory receptor protein to cancer, and selecting at least one selected from the group consisting of (1) a combination of the olfactory receptor protein A and the olfactory receptor protein C, (2) a combination of the olfactory receptor protein A ' and the olfactory receptor protein B, and (3) the olfactory receptor protein B '.SELECTED DRAWING: None

This invention discloses a method for detecting 5-hydroxymethylcytosine based on triple cascade signal amplification, belonging to the field of biochemical detection technology. The method includes the following steps: 1) preparation of 5hmC-specific glycosylation and azide labeling; 2) magnetic bead capture and enrichment separation of target DNA; 3) TdT-mediated nucleic acid end polymerization and extension; 4) APE1-triggered primer release and rolling circle amplification; 5) DNase-catalyzed cleavage and fluorescence signal detection. This invention is bisulfite-free and sequence-independent, achieving extremely low background and ultra-high sensitivity detection with a detection limit of 4.41 fM. It can be widely applied to early clinical cancer screening, biomarker detection for neurological or cardiovascular diseases, and provides a powerful platform for low-abundance epigenetic analysis in clinical diagnosis and biomedical research.

The present systems and methods relate to devices, methods, and systems for detecting the probability of cancer conditions using Sialic Acid concentrations. The present invention relates to a non-invasive system with diagnostic and treatment capacities that use a unified code that is intrinsic to physiological brain function. Embodiments may provide salivary sialic acid testing for cancer detection, for example, breast and oral cancers. Findings indicate the effectiveness of salivary sialic acid testing for detecting solid cancers, potentially serving as an initial screening tool in laboratory settings before invasive diagnostic procedures are recommended.

Cell-free DNA molecules in a mixture of biological samples can be analyzed to detect viral DNA. Methylation of viral DNA molecules at one or more sites in the viral genome can be determined. Mixture methylation level(s) can be measured based on the amount of one or more of a plurality of cell-free DNA molecules methylated at a set of specific viral genome sites(s). Mixture methylation level(s) can be determined in various ways, for example, as the density of cell-free DNA molecules methylated at a site or across multiple sites or regions. Mixture methylation level(s) can be compared, for example, with reference methylation level(s) determined from at least two cohorts of other subjects. The cohorts can have different classifications (including a first pathology) associated with a specific viral genome. A first classification of whether the subject has the first pathology can be determined based on the comparison.

The invention relates to an SERS (Surface Enhanced Raman Scattering) sensing chip as well as a preparation method and application thereof, and relates to the technical field of medical detection. The invention provides an SERS (Surface Enhanced Raman Scattering) sensing chip and a preparation method thereof, the SERS sensing chip is applied to an exhaled gas cancer screening device, exhaled gas is collected by a gas bag and is subjected to gas homogenization treatment, and the high sensitivity characteristic of a multi-target modified surface enhanced Raman scattering material is combined; accurate detection of cancer-related volatile organic compounds in exhaled air is achieved, and finally noninvasive, accurate, efficient and convenient early cancer screening is achieved.

The present invention provides systems, instruments, and methods for determining genetic or molecular distortions in a biological sample from an organism. Biological samples including free DNA fragments are analyzed to identify imbalances present in chromosomal regions, e.g., due to tumor chromosome deletion and / or amplification. Multiple loci are used for analysis of individual chromosomal regions. Such imbalances can then be used to diagnose (screen) cancer as well as prognosis of cancer patients, or to detect a patient's pre-exacerbation health status or to monitor changes in a patient's pre-exacerbation health status. Diagnosis, screening, prognosis, and monitoring can be provided using the severity of genomic imbalances, as well as the number of regions of imbalance. Systematic analysis of non-overlapping chromosome segments can provide a universal cancer screening means. Furthermore, the patient can be examined at different points in time to track one or more chromosomal regions and the severity of each of the numerous chromosomal regions and the number of chromosomal regions exhibiting chromosomal aberrations, therefore, cancer screening, prognosis diagnosis and lesion process monitoring (for example, after treatment) can be carried out.

This invention relates to a cancer signal identification method based on a cfDNA sequence language model and its application in cancer screening and MRD monitoring. The deep learning-based sequence language model analyzes whole-genome sequencing data of cfDNA to automatically extract and identify cancer-related signals, making it suitable for clinical scenarios such as early cancer screening and minimal residual disease (MRD) monitoring. This technology overcomes the limitations of targeting specific known mutations or manually labeled biomarkers, enabling end-to-end deep modeling of high-throughput whole-genome sequences of cfDNA. This significantly improves the sensitivity, specificity, and generalization ability of early cancer screening and MRD monitoring, providing an innovative solution for non-invasive screening of multiple cancer types and longitudinal disease monitoring.

The application relates to the technical field of thyroid nodule cancer screening, and specifically discloses a marker for thyroid cancer screening, a primer probe composition and application thereof. The corresponding genes of the marker are PDCD1 genes and / or RARG genes. A composition for thyroid cancer screening comprises nucleic acids for detecting target gene methylation states, wherein the target gene methylation states are characterized by methylation of target sequences of the target genes, and wherein the target genes comprise PDCD1 genes and / or RARG genes. When the marker in the application is used to screen thyroid cancer, the screening can be based on peripheral blood PBMCs without using cfDNA, and the detection method in the application has significantly improved specificity and sensitivity.

A cancer screening method takes advantage of the Warburg Effect to provide an early detection method and system. The cancer screening method includes administering a glucose solution, such as a C-13 glucose solution, measuring a metabolized lactate level in the blood of the individual after a period of time following the administration of the glucose solution, and comparing the measured lactate level to a baseline lactate level representative of noncancerous activity, and making a determination as to whether or not the measured lactate level is potentially indicative of cancer activity in the individual. The period of time is selected to be an amount of time following the glucose administration after which metabolized lactate from cancerous cells would be present in the blood and before which the metabolized lactate would be cleared or substantial amounts of non-cancerous metabolized lactate would be present in the blood of the individual.

This application relates to the field of biotechnology, specifically disclosing a methylation molecular marker and its detection kit for early warning of oral mucosal cancer. The methylation molecular markers are the ZNF582 and SHOX2 genes. This application provides important molecular information for oral cancer screening by detecting the methylation levels of the ZNF582 and SHOX2 genes. The molecular markers of this application have high accuracy, sensitivity, and specificity, providing an important reference for early warning of oral mucosal cancer. Furthermore, the detection method is simple, rapid, low-cost, and convenient to sample, which can help achieve non-invasive early warning of potential oral malignant diseases, showing promising application prospects.